Tonix Pharmaceuticals Holding (TNXP) Research & Development (2011 - 2026)

Tonix Pharmaceuticals Holding's Research & Development history runs 16 years deep, the most recent figure standing at $18.2 million for Q1 2026.

• On a quarterly basis, Research & Development rose 144.93% year-over-year to $18.2 million in Q1 2026; TTM through Mar 2026 was $55.3 million, a 59.97% increase from a year earlier, with the FY2025 full-year figure at $44.5 million, up 11.29% from the prior year.
• Research & Development improved to $18.2 million in Q1 2026 per TNXP's latest filing, from $16.9 million in the prior quarter.
• Across five years, Research & Development topped out at $26.5 million in Q1 2023 and bottomed at $7.4 million in Q1 2025.
• The 5-year median for Research & Development is $16.9 million (2025), against an average of $16.0 million.
• Across the five-year window, Research & Development tumbled 56.7% in 2024 and jumped 144.93% in 2026, its largest moves.
• Year by year, Research & Development stood at $24.7 million in 2022, then sank by 30.62% to $17.1 million in 2023, then plunged by 51.54% to $8.3 million in 2024, then surged by 104.18% to $16.9 million in 2025, then grew by 7.51% to $18.2 million in 2026.
• Per Business Quant, the three latest TNXP Research & Development figures stand at $18.2 million (Q1 2026), $16.9 million (Q4 2025), and $9.3 million (Q3 2025).